DURECT (NASDAQ:DRRX) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of DURECT (NASDAQ:DRRXGet Rating) in a research report issued to clients and investors on Thursday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.

Separately, Zacks Investment Research cut shares of DURECT from a “buy” rating to a “hold” rating in a report on Wednesday, February 23rd.

Shares of NASDAQ DRRX opened at $0.44 on Thursday. DURECT has a twelve month low of $0.43 and a twelve month high of $1.93. The firm has a fifty day simple moving average of $0.61 and a 200 day simple moving average of $0.86. The company has a market capitalization of $99.68 million, a PE ratio of -2.74 and a beta of 1.31. The company has a quick ratio of 7.94, a current ratio of 8.13 and a debt-to-equity ratio of 0.36.

DURECT (NASDAQ:DRRXGet Rating) last posted its quarterly earnings results on Monday, March 7th. The specialty pharmaceutical company reported ($0.03) EPS for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.02. The business had revenue of $7.30 million during the quarter, compared to analysts’ expectations of $2.40 million. DURECT had a negative net margin of 259.46% and a negative return on equity of 52.37%. During the same period last year, the company posted ($0.04) earnings per share. As a group, equities analysts expect that DURECT will post -0.19 earnings per share for the current fiscal year.

In other DURECT news, Director Judith J. Robertson acquired 200,000 shares of DURECT stock in a transaction dated Monday, March 14th. The stock was purchased at an average cost of $0.59 per share, for a total transaction of $118,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 4.60% of the stock is owned by company insiders.

Several institutional investors and hedge funds have recently added to or reduced their stakes in DRRX. Kovack Advisors Inc. bought a new position in shares of DURECT during the fourth quarter valued at about $25,000. Janus Henderson Group PLC bought a new position in shares of DURECT during the third quarter valued at about $29,000. Teacher Retirement System of Texas lifted its position in shares of DURECT by 35.6% during the third quarter. Teacher Retirement System of Texas now owns 35,579 shares of the specialty pharmaceutical company’s stock valued at $46,000 after purchasing an additional 9,344 shares in the last quarter. ProShare Advisors LLC lifted its position in shares of DURECT by 70.5% during the fourth quarter. ProShare Advisors LLC now owns 49,421 shares of the specialty pharmaceutical company’s stock valued at $49,000 after purchasing an additional 20,430 shares in the last quarter. Finally, Ancora Advisors LLC bought a new stake in DURECT in the third quarter worth about $50,000. 50.49% of the stock is currently owned by institutional investors.

About DURECT (Get Rating)

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.

See Also

Receive News & Ratings for DURECT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT and related companies with MarketBeat.com's FREE daily email newsletter.